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ABSTRACT 26 
The anaerobic intestinal spirochaete Brachyspira pilosicoli colonises the large intestine of 27 
humans and various species of animals and birds, in which it may induce a mild colitis and 28 
diarrhoea. The aim of the current study was to evaluate the use of putative oligopeptide-29 
binding proteins of B. pilosicoli as vaccine components. A partial genome sequence of B. 30 
pilosicoli porcine strain 95/1000 was subjected to bioinformatics analysis, and six genes 31 
predicted to encode oligopeptide-binding proteins were selected. Following a PCR-based 32 
distribution study of the genes across different strains of the spirochaete, they were amplified 33 
from B. pilosicoli human strain WesB and cloned in Escherichia coli. The recombinant 34 
histidine-tagged proteins were purified and subjected to in vitro and in vivo immunogenicity 35 
analysis. Recombinant products (P-1 and P-3) from two genes that were immunogenic and 36 
recognised by sera from pigs recovered from B. pilosicoli infections were tested in a mouse 37 
model of intestinal spirochaetosis. For each recombinant protein, groups of 12 C3H/HeJ mice 38 
were vaccinated subcutaneously with 100 μg protein emulsified in Freund’s incomplete 39 
adjuvant, twice at a two-week interval. Two weeks later the vaccinated and non-vaccinated 40 
control animals were challenged orally with B. pilosicoli strain WesB. Both proteins induced 41 
systemic and local colonic IgG antibody responses, and, following experimental infection, the 42 
cumulative number of colonisation days was significantly (P < 0.001) less in both groups of 43 
vaccinated mice compared to the control mice. There were significantly (P = 0.012) fewer 44 
mice colonised in the group vaccinated with P-1 than in the non-vaccinated control group. 45 
The results suggest that oligopeptide-binding proteins may have potential for use as 46 
components of vaccines for B. pilosicoli. 47 
48 
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INTRODUCTION 49 
Brachyspira pilosicoli is a weakly haemolytic anaerobic spirochaete which colonises the large 50 
intestine of human beings and a number of species of animals and birds, notably chickens, 51 
pigs, dogs, and horses (Hampson et al., 2006). In pigs the infection can lead to diarrhoea and 52 
poor growth rates (Hampson & Duhamel, 2006), and in adult chickens it is associated with 53 
wet faeces and reduced egg production (Hampson & Swayne, 2008). In humans, colonisation 54 
may result in various non-specific problems, including abdominal pain, chronic diarrhoea, and 55 
failure to thrive in children (Douglas & Crucioli, 1981; Peghani et al., 2000; Brooke et al., 56 
2006; Esteve et al., 2006). B. pilosicoli also has been isolated from the bloodstream of 57 
critically-ill and immunocompromised patients (Fournié-amazouz et al., 1995; Trott et al., 58 
1997b; Kanavaki et al., 2002; Bait-Merabet et al., 2008; Zeeshan et al., 2009). Although 59 
intestinal spirochaetosis (IS) caused by B. pilosicoli it is not commonly reported in the general 60 
western population, the spirochaete is found at a high prevalence amongst people who live in 61 
conditions of poor hygiene in rural areas of developing countries (Trott et al., 1997a; 62 
Margawani et al., 2004), in indigenous populations such as Australian Aboriginals (Lee & 63 
Hampson, 1992), in homosexual males (Trivett-Moore et al., 1998), and in people infected 64 
with HIV (Käsbohrer et al., 1990).  65 
 66 
Control of IS largely relies on the use of antimicrobials, although drug resistance in B. 67 
pilosicoli is quite widespread (Mortimer-Jones et al., 2008). Commercial vaccines for IS are 68 
not available, and an autogenous bacterin vaccine failed to protect pigs that were 69 
experimentally infected with B. pilosicoli (Hampson et al., 2000). Since vaccines based on 70 
recombinant proteins have been developed for the related spirochaete Brachyspira 71 
hyodysenteriae (La et al., 2004; Song et al., 2009), the use of similar recombinant proteins is 72 
worth investigating for B. pilosicoli. Oligopeptide-binding proteins (OppA) are part of the 73 
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ATP-binding cassettes (ABC) that function in the transport of proteins across the bacterial cell 74 
envelop. Different forms of these permeases may be potential virulence determinant in 75 
various bacterial species, including spirochaetes (Hiron et al., 2007; Veith et al., 2009; Wu et 76 
al., 2007). Antibodies against OppA are found in patients with early Lyme disease (Nowalk et 77 
al., 2006), and recombinant OppA has been used successfully as a vaccine to provide 78 
protection in mice experimentally infected with Yersinia pestis (Tanabe et al., 2006). The 79 
purpose of the current study was to identify genes predicted to encode OppA-like oligopeptide 80 
binding proteins in B. pilosicoli, and to test the recombinant proteins as potential vaccine 81 
candidates in a mouse model of IS. 82 
 83 
METHODS 84 
 85 
Permissions. The infections studies were conducted with the approval of the Murdoch 86 
University Animal Ethics Committee, under permit number R2104/07. 87 
 88 
Spirochaete strains and cultivation. Twenty-seven well-characterised strains of B. pilosicoli 89 
were used in the study, including 20 from pigs and seven from humans. Twenty-one of the 90 
strains were isolated in Australia, and two each were from the UK, the USA, and Italy. The 91 
strains were obtained as frozen stocks from the culture collection held at the Reference Centre 92 
for Intestinal Spirochaetes, School of Veterinary and Biomedical Sciences, Murdoch 93 
University. They were thawed, and grown on Trypticase Soy Agar plates containing 5 % (v/v) 94 
defibrinated ovine blood. The plates were incubated for 7-10 days at 37 °C in an anaerobic 95 
environment (94 % N2/6 % CO2) generated using anaerobic Gaspak Plus sachets (BBL). The 96 
purity of the cultures was examined by phase-contrast microscopy, and cells were propagated 97 
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in modified Kunkle’s pre-reduced anaerobic broth, containing 3.5 % (v/v) foetal calf serum 98 
and 0.5 % (v/v) newborn calf serum (Kunkle et al., 1986). 99 
 100 
Genomic sequencing and in silico analysis. The genome of Australian porcine B. pilosicoli 101 
strain 95/1000 was partially sequenced using a shotgun sequencing approach at the Australian 102 
Genome Research Facility, University of Queensland, under a commercial contract, as 103 
previously described (Motro et al., 2008). Phred was used for fragment assembly (Ewing et 104 
al., 1998), with subsequent viewing using Consed (Gordon et al., 1998). Open reading frame 105 
(ORF) identification was carried out using Glimmer and GeneMark (Lukashin & Borodovsky, 106 
1998; Salzberg et al., 1999). Blast (ftp.ncbi.nlm.nih.gov) was used to search for similarity 107 
between the query sequences and sequences in nucleotide database Blastn and peptide 108 
database BlastP (Altschul et al., 1990). Pfam (Bateman et al., 2002) and CDD (Marchler-109 
Bauer et al., 2003), were searched to determine the structural and functional building blocks 110 
of ORF products or protein domains. PSORTb version 2.0 (http://www.psort.org/psortb/) 111 
(Nakai, 2000), SignalP version 3.0 HMM (http://www.cbs.dtu.dk/services/SignalP/) 112 
(Bendtsen et al., 2004), LipoP (http://www.cbs.dtu.dk/services/LipoP/), and TMpred 113 
(http://www.ch.embnet.org/software/TMPRED_form.html) were used to predict the 114 
subcellular localisation of the ORF products. Six ORFs predicted to encode membrane-115 
associated oligopeptide or amino acid-binding ABC-type transporter proteins were selected 116 
for further analysis. These were given a temporary designation as ORF-1 through ORF-6, 117 
with their products given the corresponding name P-1 through P-6. The nucleotide sequences 118 
were deposited in GenBank, and the accession numbers are listed in Table 1. 119 
 120 
Gene distribution analysis by PCR. Pairs of primers that annealed to internal regions of the 121 
ORFs were designed using SeqEd Version 1.0.3 and Amplify© program version 1.2 122 
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(University of Wisconsin) (Supplementary Table 1), and the distribution of the ORFs amongst 123 
the strains of B. pilosicoli was analysed by PCR. The amplification mixtures consisted of 1 x 124 
PCR buffer, 1.5 mM MgCL2, 0.6 U of Taq DNA polymerase, 0.25 mM of each dNTP 125 
(Promega), 0.5 μM of the primer set, and 50-100 ng chromosomal DNA template in a total 126 
volume of 25 μl or 50 μl reactions. The reactions were loaded into 0.2 mL thin-walled 127 
thermocycling tubes (Multiply-Pro) and Ultrapure water (Fisher Biotech) was used to make 128 
up the reaction volume. Thermocycling conditions consisted of an initial template 129 
denaturation for 5 min at 94 °C, followed by 30-35 cycles of denaturation at 94 °C for 30 s, 130 
annealing at 57 °C for 30 s, and primer extension at 72 °C for 1-1.5 min. The final cycle had 131 
the extension time increased to 7 min to complete synthesis of all strands. The amplified 132 
products were separated by electrophoresis in 1.2 % (w/v) agarose in 1 × TAE buffer (40 mM 133 
Tris-acetate, 1 mM EDTA), stained by immersion in a 1μg mL-1 ethidium bromide solution 134 
and viewed over UV light.  135 
 136 
Preparation of recombinant histidine tagged proteins. The ORFs were amplified from 137 
human B. pilosicoli strain WesB using the primers listed in supplementary Table 2. The PCR 138 
was performed as for the gene distribution study, except for using 0.06 U of Pfu DNA 139 
polymerase and 12.5 pM of each primer. The amplified products were restricted with EcoR1 140 
and BamH1 (New England Biolabs), in a double-digest according to the manufacturer’s 141 
instructions. The restricted insert DNAs were purified using the UltraClean PCR Clean-up Kit 142 
and cloned into pTrcHis A vector (Invitrogen) according to the manufacturer’s instructions. 143 
Recombinant histidine-tagged proteins were expressed in E. coli BL21 Star TM (DE3) pLys 144 
(Invitrogen) in 2YT medium supplemented with 100 μg mL-1 ampicillin, 0.5-1 mM IPTG, and 145 
0.1 - 1 % (w/v) glucose. The recombinant His6-proteins were purified by affinity 146 
chromatography using nickel nitrilotriacetic acid metal affinity chromatography (Qiagen 147 
  
7
GmbH), conducted as described in the QIAexpressionistTM handbook. The purified proteins 148 
were dialyzed against distilled water and then lyophilised and re-suspended in phosphate 149 
buffer saline (PBS; pH 7.2). Quantification of recombinant His6-proteins was carried out by 150 
loading serial dilutions of bovine serum albumen and lysosyme protein standards (100, 250, 151 
500, 1000 ng) on an SDS-PAGE gel, then acquiring gel images using a densitometer 152 
(proxPRESS Proteomic Imaging System, PerkinElmer Life Science). The retrieving images 153 
were analyzed using the Proteome 1D Analyser version V 1.10 (PerkinElmer Life Science) to 154 
calculate the protein concentrations.  155 
 156 
Whole cell protein preparations of B. pilosicoli. Cells of B. pilosicoli strain WesB were 157 
centrifuged at 1000 g for 10 min at 4 °C, resuspended in cold PBS, and washed three times. 158 
The cells were suspended at a concentration of 108 cells mL-1 in PBS and subjected to four 159 
cycles of freeze-thawing followed by sonication on ice for four cycles of 30 s with a 2 min 160 
pause between cycles. The sonicate was centrifuged at 10,000 g for 30 min and the 161 
supernatant was separated for use in a blot assay. The total protein concentration was 162 
quantified using the Biorad Protein Assay kit, according to the manufacturer’s instructions.  163 
 164 
Preparation of mouse polyclonal antiserum against B. pilosicoli strain WesB. A whole 165 
cell bacterin was prepared from B. pilosicoli strain WesB, as previously described (Hampson 166 
et al., 2000). A total of 108 formalinised WesB cells were emulsified in an equal volume of 167 
Freund’s incomplete adjuvant (Sigma) in a total volume of 100 μl and administered 168 
subcutaneously into five C3H/HeJ male mice of five weeks of age three times at two-week 169 
intervals. Three weeks after the last inoculation, the mice were euthanased by methoxyflurane 170 
inhalation followed by cervical dislocation, blood was collected by cardiac puncture and the 171 
serum was separated and stored at -20 oC until used. 172 
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 173 
In vitro immunogenicity analysis. The recombinant proteins were tested in Western 174 
immunoblots with the mouse polyclonal antiserum against B. pilosicoli, as well as swine 175 
serum obtained from the Centre for Intestinal Spirochaete Research, Murdoch University. The 176 
sera originated from healthy pigs as well as animals naturally or experimentally infected with 177 
B. pilosicoli. 178 
 179 
SDS-PAGE gels were used to separate 10 µg of each recombinant His6-protein and these were 180 
eletro-transferred to nitrocellulose membranes, blocked with TBS-T (Tris buffered saline 181 
supplemented with 0.05 % v/v Tween 20) containing 5 % (w/v) skimmed milk powder and 182 
assembled into a multi-probe apparatus. The mouse and pig sera were diluted 50-100 fold, 183 
added to the membranes and incubated for 1 h on a shaker at room temperature followed by 184 
three washes with TBS-T. The membranes were reacted with a 1: 5000 dilution of anti-pig or 185 
anti-mouse IgG-alkaline phosphate conjugate for 1 h at room temperature. The membranes 186 
were developed with alkaline phosphatase developing buffer (BioRad), after three washes 187 
with TBS.  188 
 189 
In vivo immunogenicity analysis. Thirty-five C3H/HeJ male mice of 5 weeks of age were 190 
housed in seven groups of five in the Animal House at Murdoch University. Six groups of 191 
mice were injected subcutaneously twice at a 2 week interval with 100 μg of the appropriate 192 
His6-protein, resuspended in 50 μl PBS, and emulsified in an equal volume of Freund’s 193 
Incomplete Adjuvant in a total volume of 100 μl. The last group of mice was left 194 
unvaccinated. Two weeks after the last inoculation, all the mice were euthanased and the 195 
blood was collected as described previously. The immunogenicity of each recombinant 196 
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protein was confirmed using Western blot against whole cell protein preparations of B. 197 
pilosicoli strain WesB and each recombinant His6-protein. 198 
 199 
Vaccine efficacy study. Two selected recombinant proteins (P-1 and P-3) were tested as 200 
candidate vaccine antigens against IS in C3H/HeJ mice. Seventy-two female mice of 5-weeks 201 
of age were housed in six groups of 12 per cage. The mice were fed on a commercial pelleted 202 
basal mouse diet from their arrival until 10 days before the day of first infection with B. 203 
pilosicoli, and then the diet was changed to a balanced diet containing 63% glucose that has 204 
been reported to support infection with B. pilosicoli in mice (Sacco et al., 1997). The mice 205 
were killed 16 days after the last day of experimental infection. 206 
 207 
For each recombinant protein, 12 mice were used as a vaccinated/non-infected group and 12 208 
as a vaccinated/infected group. The mice were injected subcutaneously twice at a 2 week 209 
interval with 100 μg of the appropriate His6-P recombinant protein emulsified in Freund’s 210 
Incomplete Adjuvant in a total volume of 100 μl. Two control groups each of 12 mice were 211 
included, comprising non-vaccinated/infected (infection control) and non-vaccinated/non-212 
infected (negative control) mice. Two weeks after the second vaccination, the mice in the 213 
vaccinated/non-infected groups were killed to obtain blood and intestinal samples to analyse 214 
systemic and local antibody responses to the vaccines. The mice in the vaccinated/infected 215 
groups, and the infection control group were deprived of water for 1 h, then they were 216 
infected via gastric intubation with 500 μl of fresh motile B. pilosicoli strain WesB culture at 217 
mid-exponential phase growth at a density of approximately 108 cells mL-1. The inoculation 218 
procedure was repeated daily on the following 3 days. The negative control group was not 219 
infected and the mice were killed at the end of the experiment to collect blood and intestine 220 
samples. 221 
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 222 
Faecal sampling, culture and DNA detection. Faecal pellets (3 - 4) from each mouse were 223 
collected before vaccination, before infection, and twice a week thereafter, starting 3 days 224 
after the last oral inoculation. Bacteriological swabs were inserted into the faeces, streaked 225 
onto selective TSA-CSV plates (Jenkinson & Wingar, 1981), and incubated for 7 – 10 d at 37 226 
ºC in an anaerobic environment before being examined. The presence of spirochaetes was 227 
identified by a zone of weak beta-haemolysis surrounding a low flat haze of bacterial growth. 228 
The growth was examined by phase-contrast microscopy and then resuspended in 50 µl lysis 229 
buffer (TE, pH 8). The suspension was mixed by vortex and then heated in a boiling water 230 
bath for 5 min. The extracts were subjected to a B. pilosicoli-specific PCR (La et al., 2003). 231 
The products were separated by electrophoresis in a 1.2 % agarose gel, stained by immersion 232 
for 30 min in ethidium bromide solution, and viewed over UV light. 233 
  234 
Similar faecal samples collected pre-vaccination, post-vaccination, and at post-mortem were 235 
prepared for measuring antibody content. A 500 µl volume of cold PBS containing 5 % skim 236 
milk and 0.5 % proteinase inhibitor was added to each sample and incubated at 4 °C overnight 237 
until dissolved. After mixing by vortex the supernatant was collected by centrifugation at 238 
16,000 g for 10 min and stored at -20 °C until used. Blood collected by heart puncture at post-239 
mortem was allowed to stand overnight at 4 ºC, the clot was removed, and the serum was 240 
centrifuged at 2000 g for 10 min at 4 °C to pellet the debris. The sera were removed, mixed 241 
with an equal volume of 100 % glycerol and stored at -20 °C.  242 
 243 
Post-mortem tissue and faecal samples. The luminal surface of the caecal and colon walls 244 
were rubbed with sterile bacteriological swabs, and cultured for B. pilosicoli as described for 245 
faecal swabs. Contents equal to 3 - 4 faecal pellets were collected from the caecum and colon 246 
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into 500 µl of cold PBS containing 5 % skim milk and 0.5 % of proteinase inhibitor for 247 
antibody quantification. Sections of the caecal and colon walls were excised and rinsed in 248 
cold PBS to remove digesta and then were placed in 10 % (v/v) buffered formalin for 249 
histological examination. The fixed tissue was processed through to paraffin blocks, cut at 4 250 
µm and stained with haematoxylin and eosin. 251 
 252 
Assays for antibody responses. After being optimised, enzyme-linked immunoabsorbent 253 
assays (ELISA) and Western immunoblots were used to evaluate the systemic and mucosal 254 
IgG and IgA responses against the recombinant proteins. The ELISA used 100 ng either of 255 
each recombinant protein or a whole cell protein preparation of B. pilosicoli per well in 0.1 M 256 
carbonate buffer (pH 9.6) plus blocking solution (TBS-T containing 5 % (w/v) skimmed milk 257 
powder) and mouse serum (1:200) or faecal extract (1:2). Positive ELISA samples also were 258 
analysed by Western blot using either 3000 ng of recombinant protein or 5000 ng of whole 259 
cell B. pilosicoli protein preparation as antigen. The procedure was as previously described 260 
except that goat anti-mouse IgG-HRP or IgA-HRP conjugate at 1:4000 dilution were used to 261 
detect mouse primary antibodies, and horseradish peroxidase substrate solution (HRP 10 mg, 262 
16.6 mL PBS pH 7.4, 3.325 mL methanol and 10 µL of hydrogen peroxide) was used to 263 
develop the colour.  264 
 265 
Data analysis and statistics. Comparisons were made between the groups of mice. The 266 
ELISA values for group systemic and local IgG were calculated as means ± standard 267 
deviations. The statistical differences of the ELISA values between groups of mice in each 268 
experiment were analysed using one-way analysis of variance in Microsoft Office Excel. 269 
Faecal excretion of B. pilosicoli for each animal in each group was recorded as positive or 270 
negative to create a simple ratio of infected samples per total samples collected for each 271 
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group. The ratios for each group were compared using Chi-square analysis, with pairs of 272 
observations subsequently analysed using Fischer’s exact test.  273 
 274 
RESULTS 275 
Characteristics and distribution of selected ORFs. A summary of the bioinformatics 276 
analysis on the six selected ORFs is presented in Table 1. The ORF were predicted to encode 277 
membrane associated periplasmic proteins involved in ABC-type oligopeptide or amino acid 278 
transport. PCR analysis identified all six ORFs in 93-100 % of the 27 B. pilosicoli strains 279 
tested. ORF-1 and ORF-2 were not amplified from two Australian porcine strains of B. 280 
pilosicoli, and ORF-3 was not amplified from another Australian porcine strain. The other 281 
three ORFs were amplified from all the strains. 282 
    [Table 1 about here] 283 
Recombinant protein expression, purification and immunogenicity. All six proteins were 284 
successfully expressed in E. coli BL21, and purified by affinity chromatography. The 285 
molecular masses of the mature proteins as seen on the SDS-PAGE gels were similar to their 286 
predicted masses (Table 1). Five were strongly immunoreactive in Western immunoblots with 287 
a set of sera from convalescent pigs, while P-4 was weakly reactive. A similar pattern was 288 
seen with mouse sera raised against a bacterin preparation of B. pilosicoli strain WesB. Weak 289 
Western blot reactivities also were observed between the negative control sera and all the 290 
proteins except for P-4. Sera obtained by immunising mice with the proteins were 291 
immunoreactive with their corresponding recombinant proteins, and with their specific native 292 
proteins in the whole cell preparation of B. pilosicoli strain WesB. Results for recombinant 293 
proteins P-1 and P-3 are shown in Figure 1. 294 
    [Figures 1 about here] 295 
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Antibody responses in vaccinated and infected mice. The systemic and large intestinal IgG 296 
responses of the mice immunized with P-1 and P-3 in the vaccine experiment are summarised 297 
in Table 2. Vaccinated mice had significantly more serum IgG against the corresponding 298 
proteins than did non-vaccinated mice. In contrast, infection alone did not significantly 299 
increase antibody levels to these proteins. Vaccination with P-1 but not P-3 resulted in a 300 
further significant increase in serum antibody levels in vaccinated infected mice compared to 301 
vaccinated non-infected mice. Vaccination also resulted in a significant increase in local IgG 302 
levels to the corresponding proteins in the mixed samples from the caecae and colons, 303 
although this increase was considerably greater with P-1 than with P-3. Infection also resulted 304 
in significant increases in IgG levels in the case of P-1. Infection of vaccinated mice only 305 
further significantly increased IgG levels in the case of P-3. No IgA to the recombinant 306 
proteins was detected.  307 
   [Table 2 about here] 308 
Faecal shedding of B. pilosicoli. The colonisation rates are summarised in Table 3. No mice 309 
were colonised pre-infection. Colonisation was first observed at day 6, and was greatest at day 310 
16, when 9 of the 12 control mice were colonised. The ratio of positive samples/total samples 311 
obtained was significantly greater (P < 0.001) for the infection control mice compared to both 312 
groups of vaccinated mice. Significantly fewer mice vaccinated with P-1 were colonised 313 
compared to the control mice (P = 0.012), but differences in numbers were not significant for 314 
the mice vaccinated with P-3. 315 
 [Table 3 about here] 316 
Clinical signs and pathological changes. The caecae and colons of the colonised mice did 317 
not show obvious gross changes compared to those of non-colonised mice. Histological 318 
examination revealed some mild abnormalities such as an increase in the number of goblet 319 
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cells and focal disruption of the epithelium in both caecal and colonic samples of the 320 
colonised mice, but no end-on attachment of spirochaetes to enterocytes was observed. 321 
 322 
DISCUSSION 323 
The mouse model of IS adapted in the current study was based on that used by Sacco et al., 324 
(1997), including feeding a disaccharide-rich diet and using C3H/HeJ mice. The model 325 
worked reasonably well, with 75 % of the non-vaccinated control animals becoming 326 
colonised; however, end-on attachment of spirochaetes was not observed, and colonisation did 327 
not induce clinical signs or consistent pathological changes. In a previous study, the same B. 328 
pilosicoli strain (WesB) similarly failed to attach to colonic enterocytes or cause obvious 329 
pathology in a mouse model of IS (Jamshidian et al., 2004). Despite this limitation, vaccine 330 
efficacy could be judged in relation to colonisation rates in this model. 331 
 332 
The aim of the study was to determine whether immunisation with Opp-like oligopeptide-333 
binding proteins from B. pilosicoli could protect from IS, based on the report that recombinant 334 
Opp has shown efficacy against Y. pestis infection in mice (Tanabe et al., 2006). To achieve 335 
this, a small number of genes predicted to encode membrane-associated oligopeptide-binding 336 
proteins in B. pilosicoli were selected from an incomplete genome sequence. Clearly, in future 337 
studies, it also would be possible to use the same “reverse vaccinology” process, starting with 338 
the genome sequence, to select and test other classes of potential vaccine candidates, such as 339 
outer membrane lipoproteins and secreted proteins (Movahedi & Hampson, 2008). The genes 340 
that were selected in the current study were widely distributed amongst different B. pilosicoli 341 
strains, indicating that if the products were effective as vaccine components against one strain 342 
they probably would be effective against a wide range of strains. The corresponding 343 
recombinant proteins were all immunogenic in mice, and they were recognised by serum from 344 
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naturally or experimentally infected pigs. This finding supported the likelihood that these 345 
molecules could induce an immune response with potential to protect from infection. 346 
Reactivity to P-4 was weaker than to the other proteins, and so it was excluded on that basis. 347 
Interestingly, P-4 was the only molecule that was not predicted to be a lipoprotein. P-5 and P-348 
6 were predicted to be involved in amino acid transport rather than oligopeptide transport, so 349 
these were not selected for testing in mice. Two of the remaining three recombinant proteins 350 
were predicted to have signal peptides, suggesting that they were secretory, and one of each 351 
sort were selected for testing in the mouse model of IS. 352 
 353 
As anticipated, the experimental vaccines induced significant increases in systemic IgG levels 354 
against the corresponding proteins. The subcutaneous route of vaccine administration induced 355 
a mucosal IgG antibody response in the large intestine, although this was only relatively high 356 
in the case of P-1. Infection alone also induced a similar local response against P-1. Infection 357 
of vaccinated mice further significantly increased systemic IgG only in the case of P-1, 358 
whereas there was an increased antibody response to P-3 but not to P-1 followed infection of 359 
the vaccinated mice. The lack of a local IgA response in the infected mice was unexpected, 360 
but in part this may reflect the relatively short period that the mice were kept in the 361 
experiments.  362 
 363 
Both vaccinated groups had significantly fewer days of colonisation than did the infection 364 
control group, hence providing evidence that the vaccines were having some effects in 365 
reducing colonisation. Furthermore, vaccination with P-1, which induced the highest levels of 366 
systemic and local IgG, also significantly reduced the number of colonised mice. Further 367 
studies are now required to test these recombinant proteins as vaccine candidates in other 368 
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natural hosts, such as chickens and pigs. In addition, a more detailed investigation of the 369 
structure and function of these predicted oligopeptide-binding proteins is required. 370 
 371 
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Figure legend 
 
Figure 1. Western immunoblots showing the reactivities of the two recombinant 
proteins used in the mouse vaccination experiments. Panels A and B, reactivity of 
recombinant P-1 and P-3, respectively, with serum from mice immunised with these 
proteins. Panels C and D, reactivity of the same mouse sera shown in panels A and B, 
respectively, with a whole cell preparation of B. pilosicoli strain WesB. Lanes 1-5, 
serum samples from non-vaccinated mice. Lanes 6-10, serum samples from mice 
vaccinated with the respective recombinant proteins. M, protein mass marker. The 
arrows indicate the position of the reactive proteins. Their molecular masses are 
similar to the predicted molecular masses (Table 1). 
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Table 1. Results of bioinformatics analysis on six ORFs selected for further analysis.  
Temporary 
locus ID 
GenBank 
accession 
number 
Putative identity (E-value) Signal 
peptide 
(SignalP) 
TM helices 
(TMpred) 
Lipoprotein 
(LipoP 1.0) 
Theoretical molecular 
mass of product 
(Kilodaltons) 
ORF-1 GQ478427 ABC-type oligopeptide 
transport system (1e-121) 
No 2 Yes 60.35 
ORF-2 GQ478428 ABC-type oligopeptide 
transport system (1e-114) 
Yes 1 Yes 61.10 
ORF-3 GQ478429 ABC-type oligopeptide 
transport system (2e-75) 
Yes 2 Yes 39.40 
ORF-4 GQ478430 ABC-type oligopeptide 
transport system (3e-73) 
No 1 No 36.04 
ORF-5 GQ478431 ABC-type amino acid 
transport system (3e-61) 
Yes  1 Yes 30.52 
ORF-6 GQ478432 ABC-type amino acid 
transport system (2e-61) 
Yes 1 Yes 30.31 
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Table 2. Means and standard deviations of group systemic and local large intestinal IgG levels (OD values) against the  
recombinant proteins in vaccinated and non-vaccinated mice that were either not infected or infected with B. pilosicoli 
 
ELISA 
antigen / 
vaccine 
group 
 Non-infected Infected *P-value 
(ANOVA) 
Antibody Non-vaccinated  Vaccinated Non-vaccinated 
/ Infected 
Vaccinated / Infected  
P-1 Systemic 0.198 ± 0.039a 2.935 ± 0.153b 0.277± 0.114a 3.211± 0.123c <0.001 
 Local 0.036±0.004a 1.263 ± 0.47c 0.101 ± 0.036b 1.434 ± 0.581c <0.001 
P-3 Systemic 0.134 ± 0.059a 2.195 ± 0.444b 0.078 ± 0.012a 2.608 ± 0.417b <0.001 
 Local 0.040 ± 0.004a 0.192 ± 0.089b 0.058 ± 0.007a 0.327 ± 0.117c <0.001 
 
* Within each row, values with a different superscript letter differ at the 5 % level of significance. 
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Table 3. Number of colonised mice and cumulative group colonisation results for the groups 
of 12 vaccinated and non-vaccinated mice orally challenged with B. pilosicoli.  
 
    Days post-infection  
Group 3 6 9 12 16 Positive samples / 
total samples* 
Number of 
colonised mice† 
P-1 vaccinated 0 1 2 2 2 7/60 2 
P-3 vaccinated 0 2 3 3 4 12/60 5 
Infection control 0 4 7 9 9 29/60 9 
 
*The ratio was significantly greater (P < 0.001) for the infection control mice compared to 
both groups of vaccinated mice.  
†Significantly fewer mice vaccinated with P-1 were colonised compared to the control mice 
(P = 0.012). Other differences were not significant. 
 
Fig 1
M         1        2       3       4        5       6        7       8       9     10
75
kDa
50
37
25
20
75
M         1        2       3       4      5       6       7       8        9     10kDa
50
37
25
20
A
C
50
37
25
20
kDa
75
M         1        2        3       4       5       6       7       8        9      10
B
D
75
50
M         1      2      3      4       5       6       7       8      9     10kDa
25
37
20
